Regulation of Cancer-Associated miRNAs Expression under Hypoxic Conditions
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Hypoxia-inducible factor 1 alpha (HIF-1α) activation in solid tumors regulates microRNAs (miRNAs), impacting cancer cell adaptation and progression. This review explores how hypoxia influences miRNA expression in cancer development.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Solid tumors often exhibit hypoxic conditions, creating an environment that promotes cancer cell survival and proliferation.
- Hypoxia-inducible factor 1 alpha (HIF-1α) is a key transcription factor activated by low oxygen levels.
- MicroRNAs (miRNAs) are small noncoding RNAs crucial for regulating gene expression in various biological processes, including cancer progression.
Purpose Of The Study
- To review the regulatory mechanisms by which hypoxia influences the expression of microRNAs in cancer cells.
- To highlight the role of HIF-1α in mediating hypoxia-induced miRNA alterations.
- To discuss the implications of these miRNA changes in cancer cell adaptation and progression.
Main Methods
- Literature review of studies investigating hypoxia, HIF-1α, and miRNA expression in solid tumors.
- Analysis of signaling pathways regulated by HIF-1α in response to hypoxic stress.
- Examination of the functional impact of hypoxia-regulated miRNAs on cancer cell proliferation, survival, and adaptation.
Main Results
- Hypoxia significantly alters the expression profiles of numerous miRNAs within solid tumors.
- HIF-1α activation is a central mediator of hypoxia-induced miRNA dysregulation.
- Altered miRNA expression contributes to cancer cell adaptation to nutrient and oxygen deprivation, promoting proliferation and survival.
Conclusions
- Hypoxia-driven changes in miRNA expression, orchestrated by HIF-1α, are critical determinants of cancer progression.
- Targeting hypoxia-regulated miRNAs presents a potential therapeutic strategy for solid tumors.
- Further research is needed to fully elucidate the complex interplay between hypoxia, HIF-1α, and miRNAs in oncogenesis.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
In most mammals, females have two X chromosomes (XX) while males have an X and a Y chromosome (XY). The X chromosome contains significantly more genes than the Y chromosome. Therefore, to prevent an excess of X chromosome-linked gene expression in females, one of the two X chromosomes is randomly silenced during early development....
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...